[{"orgOrder":0,"company":"Quratis Co., Ltd","sponsor":"HDT Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"HDT-301","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Quratis Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Quratis Co., Ltd \/ Quratis Inc","highestDevelopmentStatusID":"9","companyTruncated":"Quratis Co., Ltd \/ Quratis Inc"},{"orgOrder":0,"company":"Quratis Co., Ltd","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Quratis Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Quratis Co., Ltd \/ Quratis","highestDevelopmentStatusID":"6","companyTruncated":"Quratis Co., Ltd \/ Quratis"}]

Find Clinical Drug Pipeline Developments & Deals by Quratis Co., Ltd

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Company RNA-based vaccine, HDT-301 (HGCO19) offers simpler manufacturing, greater stability, and vastly lower effective dosing than current mRNA COVID-19 vaccines.

                          Brand Name : HDT-301

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          December 13, 2021

                          Lead Product(s) : HGCO19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : HDT Biotech

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : This agreement will enable Quratis to manufacture HDT Bio's next-generation COVID-19 vaccine, HGCO19 and distribute it across much of East Asia.

                          Brand Name : HGCO19

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          August 16, 2021

                          Lead Product(s) : HDT-301

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Recipient : HDT Biotech

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank